Showing results (371-380 of 662) with videos related to
Sort By:
Pageof 67
The Journal of Infectious Diseases|April 22, 2017
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral TherapyCynthia L Gay, Ronald J Bosch, Justin Ritz, et al.Journal of Virology|May 26, 2017
Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus MonkeysBoris Julg, Amarendra Pegu, Peter Abbink, et al.Frontiers in Immunology|November 11, 2021
Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living With HIVWilbert Mbuya, Kathrin Held, Ruby D Mcharo, et al.Plos One|August 9, 2016
HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected SubjectsJohannes S Gach, Andrea Gorlani, Emmanuel Y Dotsey, et al.Clinical and Vaccine Immunology : CVI|September 22, 2006
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trialJulie E Martin, Nancy J Sullivan, Mary E Enama, et al.Science Translational Medicine|October 9, 2024
A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivoJohn Misasi, Ronnie R Wei, Lingshu Wang, et al.Cell|July 26, 2016
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A VirusesM Gordon Joyce, Adam K Wheatley, Paul V Thomas, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2015
H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin StemAdam K Wheatley, James R R Whittle, Daniel Lingwood, et al.Plos One|October 27, 2015
HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell MaturationLucie Colineau, Angeline Rouers, Takuya Yamamoto, et al.Vaccine|October 1, 2008
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialJulie E Martin, Mark K Louder, LaSonji A Holman, et al.Pageof 67